Cargando…

Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma

BACKGROUND: Palliative chemotherapy has been the mainstay treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). However, little is known about the efficacy and toxicity of nimotuzumab (NTZ) – a monoclonal antibody drug targeting epidermal growth factor receptor – pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yunshu, Yang, Sheng, Zhou, Shengyu, Yang, Jianliang, Qin, Yan, Gui, Lin, Shi, Yuankai, He, Xiaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498835/
https://www.ncbi.nlm.nih.gov/pubmed/32973932
http://dx.doi.org/10.1177/1758835920953738
_version_ 1783583597923401728
author Zhu, Yunshu
Yang, Sheng
Zhou, Shengyu
Yang, Jianliang
Qin, Yan
Gui, Lin
Shi, Yuankai
He, Xiaohui
author_facet Zhu, Yunshu
Yang, Sheng
Zhou, Shengyu
Yang, Jianliang
Qin, Yan
Gui, Lin
Shi, Yuankai
He, Xiaohui
author_sort Zhu, Yunshu
collection PubMed
description BACKGROUND: Palliative chemotherapy has been the mainstay treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). However, little is known about the efficacy and toxicity of nimotuzumab (NTZ) – a monoclonal antibody drug targeting epidermal growth factor receptor – plus chemotherapy (CT) versus CT alone for these patients. METHODS: The database at Cancer Hospital of Chinese Academy of Medical Sciences was queried for patients diagnosed with NPC who received CT with or without NTZ between 2004 and 2018. Treatment compliance, survival outcomes, and adverse effects were compared among these groups. RESULTS: Records of 70 patients with R/M-NPC were reviewed: 21 (30%) received NTZ plus CT (NTZ+CT) and 49 (70%) received CT. CT regimens included gemcitabine plus platinum, taxane plus platinum (TP), and fluorouracil plus platinum. Comparing the CT group with NTZ+CT group, the median follow up was 62 months (range = 3–133) versus 59 months (range = 9–117); median progression free survival was 7.5 [95% confidence interval (CI) 6.552–8.381] months versus 8.5 (95% CI 6.091–10.976) months, p = 0.424; median overall survival (OS) was 25.6 (95% CI 18.888–32.379) months versus 48.6 (95% CI 35.619–61.581) months, p = 0.017, respectively. Multivariable analysis established treatment group (CT versus NTZ+CT) as an independent prognostic factor for OS (hazard ratio, 0.5; 95% CI 0.255–0.979; p = 0.043). No significant difference with regard to toxicities was observed between the two groups. Among them, a subgroup analysis was performed in 53 (75.7%) patients who received TP with or without NTZ, which showed similar results. CONCLUSION: Our findings suggested that NTZ+CT provides a novel treatment option and prolongs survival significantly for R/M-NPC.
format Online
Article
Text
id pubmed-7498835
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-74988352020-09-23 Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma Zhu, Yunshu Yang, Sheng Zhou, Shengyu Yang, Jianliang Qin, Yan Gui, Lin Shi, Yuankai He, Xiaohui Ther Adv Med Oncol Original Research BACKGROUND: Palliative chemotherapy has been the mainstay treatment for patients with recurrent or metastatic nasopharyngeal carcinoma (R/M-NPC). However, little is known about the efficacy and toxicity of nimotuzumab (NTZ) – a monoclonal antibody drug targeting epidermal growth factor receptor – plus chemotherapy (CT) versus CT alone for these patients. METHODS: The database at Cancer Hospital of Chinese Academy of Medical Sciences was queried for patients diagnosed with NPC who received CT with or without NTZ between 2004 and 2018. Treatment compliance, survival outcomes, and adverse effects were compared among these groups. RESULTS: Records of 70 patients with R/M-NPC were reviewed: 21 (30%) received NTZ plus CT (NTZ+CT) and 49 (70%) received CT. CT regimens included gemcitabine plus platinum, taxane plus platinum (TP), and fluorouracil plus platinum. Comparing the CT group with NTZ+CT group, the median follow up was 62 months (range = 3–133) versus 59 months (range = 9–117); median progression free survival was 7.5 [95% confidence interval (CI) 6.552–8.381] months versus 8.5 (95% CI 6.091–10.976) months, p = 0.424; median overall survival (OS) was 25.6 (95% CI 18.888–32.379) months versus 48.6 (95% CI 35.619–61.581) months, p = 0.017, respectively. Multivariable analysis established treatment group (CT versus NTZ+CT) as an independent prognostic factor for OS (hazard ratio, 0.5; 95% CI 0.255–0.979; p = 0.043). No significant difference with regard to toxicities was observed between the two groups. Among them, a subgroup analysis was performed in 53 (75.7%) patients who received TP with or without NTZ, which showed similar results. CONCLUSION: Our findings suggested that NTZ+CT provides a novel treatment option and prolongs survival significantly for R/M-NPC. SAGE Publications 2020-09-16 /pmc/articles/PMC7498835/ /pubmed/32973932 http://dx.doi.org/10.1177/1758835920953738 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Zhu, Yunshu
Yang, Sheng
Zhou, Shengyu
Yang, Jianliang
Qin, Yan
Gui, Lin
Shi, Yuankai
He, Xiaohui
Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
title Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
title_full Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
title_fullStr Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
title_full_unstemmed Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
title_short Nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
title_sort nimotuzumab plus platinum-based chemotherapy versus platinum-based chemotherapy alone in patients with recurrent or metastatic nasopharyngeal carcinoma
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498835/
https://www.ncbi.nlm.nih.gov/pubmed/32973932
http://dx.doi.org/10.1177/1758835920953738
work_keys_str_mv AT zhuyunshu nimotuzumabplusplatinumbasedchemotherapyversusplatinumbasedchemotherapyaloneinpatientswithrecurrentormetastaticnasopharyngealcarcinoma
AT yangsheng nimotuzumabplusplatinumbasedchemotherapyversusplatinumbasedchemotherapyaloneinpatientswithrecurrentormetastaticnasopharyngealcarcinoma
AT zhoushengyu nimotuzumabplusplatinumbasedchemotherapyversusplatinumbasedchemotherapyaloneinpatientswithrecurrentormetastaticnasopharyngealcarcinoma
AT yangjianliang nimotuzumabplusplatinumbasedchemotherapyversusplatinumbasedchemotherapyaloneinpatientswithrecurrentormetastaticnasopharyngealcarcinoma
AT qinyan nimotuzumabplusplatinumbasedchemotherapyversusplatinumbasedchemotherapyaloneinpatientswithrecurrentormetastaticnasopharyngealcarcinoma
AT guilin nimotuzumabplusplatinumbasedchemotherapyversusplatinumbasedchemotherapyaloneinpatientswithrecurrentormetastaticnasopharyngealcarcinoma
AT shiyuankai nimotuzumabplusplatinumbasedchemotherapyversusplatinumbasedchemotherapyaloneinpatientswithrecurrentormetastaticnasopharyngealcarcinoma
AT hexiaohui nimotuzumabplusplatinumbasedchemotherapyversusplatinumbasedchemotherapyaloneinpatientswithrecurrentormetastaticnasopharyngealcarcinoma